Teva Pharmaceutical Industries Limited TEVA and its partner, Biolojic Design Ltd., announced that TEVA has initiated investigational new drug or IND-enabling studies on BD9, a dual-specific ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter ...

BD9 blocks both TSLP and IL-13, two major drivers of TH2 inflammation. Biolojic to receive milestone payments tied to BD9 development progress. Get stock picks, daily rankings, and pro-level ...

Truist Securities launched its coverage of Teva Pharmaceutical (NYSE:TEVA) with a Buy recommendation on Wednesday, citing its long-term growth strategy as the generic drugmaker prepares to host ...

Now, the FDA has said it will carry out a speedy review of a Teva medicine that it hopes can change that. The US regulator has awarded fast-track status for TEV-53408, an anti-IL-15 antibody ...

REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ("Biolojic”), a biotechnology ...

“Teva is driven by a commitment to innovation and this latest achievement gets us one step closer to providing promising, innovative treatment options for patients with chronic autoimmune ...

Teva has an exclusive license to develop BD9 for the treatment of TH2-driven inflammatory diseases such as atopic dermatitis and asthma. Teva's development of BD9 demonstrates the company's ...

Teva Pharmaceutical Industries (NYSE:TEVA), with a market capitalization of $19.3 billion, stands as a prominent player in the global pharmaceuticals industry. According to InvestingPro data, the ...

On Tuesday, Truist Securities began coverage on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), issuing a Buy rating and setting a price target of $25.00.The announcement from ...